Stock Events

Stock Events

Healios K.K. 

$2.2
12
+$0+0% Tuesday 18:58

Statistics

Day High
2.7
Day Low
2.7
52W High
4.45
52W Low
1.9
Volume
200
Avg. Volume
21
Mkt Cap
240.79M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.19
-0.09
0.02
0.12
Expected EPS
-0.06915204
Actual EPS
N/A

Financials

-773.54%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
7.38MRevenue
-57.11MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HLOSF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap2.14B
Mesoblast Limited specializes in developing regenerative medicine products, which puts them in direct competition with Healios in the cell therapy market.
Biolife Solutions
BLFS
Mkt Cap1.34B
BioLife Solutions, Inc. provides bioproduction tools and services, including cell and gene therapy solutions, which are essential for companies like Healios, positioning them as indirect competitors.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG is focused on gene editing and gene therapy, areas that overlap with Healios's work in regenerative medicine and cell therapy.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine, Inc. is involved in gene editing, a cutting-edge area of biotechnology that competes with Healios's regenerative medicine and cell therapy technologies.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics, Inc. specializes in CRISPR/Cas9 gene editing, competing in the broader market of genetic and cell therapy that Healios is also targeting.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals, some of which may compete with Healios's products in the regenerative medicine market.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics, Inc. focuses on genomic medicine, including gene therapy, gene editing, and cell therapy, making them a competitor in the same innovative sectors as Healios.

About

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
Show more...
CEO
Dr. Tadahisa S. Kagimoto M.D.
Employees
65
Country
JP
ISIN
JP3835100003

Listings

F
DE
6VX.F
TSE
JP
4593.TSE
OTC Link
US
HLOSF

0 Comments

Share your thoughts

FAQ

What is Healios K.K. stock price today?▼
The current price of HLOSF is $2.2 USD — it has increased by +0% in the past 24 hours. Watch Healios K.K. stock price performance more closely on the chart.
What is Healios K.K. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Healios K.K. stocks are traded under the ticker HLOSF.
What is Healios K.K. market cap?▼
Today Healios K.K. has the market capitalization of 240.79M
When is the next Healios K.K. earnings date?▼
Healios K.K. is going to release the next earnings report on May 08, 2026.
What were Healios K.K. earnings last quarter?▼
HLOSF earnings for the last quarter are 0.12 USD per share, whereas the estimation was 0.03 USD resulting in a +306.46% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Healios K.K. revenue for the last year?▼
Healios K.K. revenue for the last year amounts to 7.38M USD.
What is Healios K.K. net income for the last year?▼
HLOSF net income for the last year is -57.11M USD.
How many employees does Healios K.K. have?▼
As of April 02, 2026, the company has 65 employees.
In which sector is Healios K.K. located?▼
Healios K.K. operates in the Health Care sector.
When did Healios K.K. complete a stock split?▼
Healios K.K. has not had any recent stock splits.
Where is Healios K.K. headquartered?▼
Healios K.K. is headquartered in Tokyo, JP.